Close menu




July 9th, 2024 | 07:07 CEST

Varta, Cardiol Therapeutics, Evotec - ATTENTION: Something is happening here!

  • Biotechnology
  • Pharma
  • Biotech
Photo credits: pixabay.com

The stock markets are currently seeing increased activity in Varta, Cardiol Therapeutics, and Evotec. Investors should take advantage of the resulting opportunities. Increased volatility and trading volumes can offer attractive short-term gains, while improved liquidity facilitates entry and exit. Additional information flows and momentum effects enhance the dynamics of these stocks, although they also carry increased risks. Sound analysis and prudent risk management are, therefore, essential. We take a closer look at what is currently happening with these three stocks.

time to read: 4 minutes | Author: Armin Schulz
ISIN: VARTA AG O.N. | DE000A0TGJ55 , CARDIOL THERAPEUTICS | CA14161Y2006 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Varta - Porsche to the rescue?

    Varta has been in crisis for some time. The Ellwangen-based company recently reported that it was revising its revenue forecast for 2024 due to weak business developments. The expectations are now between EUR 820 and 870 million and thus significantly below the previously expected EUR 900 million. The market for energy storage systems was particularly weak in the second quarter. Prices here slumped by around 20%. Varta is currently struggling with a sharp deterioration in the market environment and internal difficulties. Delays in launching new products, such as the high-voltage storage system VARTA.wall, are also affecting revenue development.

    A possible rescue could come from Porsche. The Stuttgart-based company is interested in acquiring a majority stake in the Varta subsidiary V4Drive Battery GmbH, which produces large-format lithium-ion cells. A non-binding letter of intent has already been signed. Even if Porsche's investment initially benefits the subsidiary, it could give Varta stability in the medium term. However, some uncertainties remain, such as the ongoing due diligence process and the approval of the major Varta shareholders. The latter would thus be giving up a piece of Varta's crown jewels, as there were high hopes for the V4Drive battery.

    On the other hand, the shareholders do not have much choice left. The restructuring measures are taking longer, and the Company is burdened by high debts. Further development is critical in the battery business if the Company does not want to fall behind. However, significant investments are out of the question at the moment. Many things are coming together for Varta at the moment: a sluggish economy, increased costs in Germany, a hacker attack, and much more. An investment by Porsche seems like winning the lottery. The news sent the share price soaring to its current level of EUR 11.34. Nevertheless, investors should not bet on a major turnaround.

    Cardiol Therapeutics - Successful Phase II study

    Cardiol Therapeutics specializes in the development of therapies for inflammatory and fibrotic heart diseases, especially for rare diseases such as recurrent pericarditis and acute myocarditis. The Company's lead candidate, CardiolRx™, is an oral formulation specifically designed to target these conditions. CardiolRx™ offers the benefit of relieving inflammation without significant adverse side effects often associated with traditional treatments such as NSAIDs, colchicine, and corticosteroids. This unique formulation has received Orphan Drug Designation from the FDA for pericarditis and is also showing promise for acute myocarditis.

    Cardiol Therapeutics’ Phase II MAvERIC-Pilot study, which investigated the efficacy and safety of CardiolRx™ in recurrent pericarditis, shows promising results. In 27 patients in the US, eight weeks of treatment showed a significant reduction in pericarditis pain and normalization of C-reactive protein (CRP), an inflammatory marker, in 80% of patients. These results suggest that CardiolRx™ could be an effective treatment option for patients who have not responded adequately to previous therapies. The high success rates could improve the quality of life of those affected and set new standards in treatment.

    Cardiol Therapeutics is also developing a subcutaneous formulation specifically for heart failure, called CRD-38. This method aims to reduce dosing frequency while maintaining therapeutic efficacy. Previous pre-clinical studies have shown this delivery method to be effective in the treatment of heart failure. The Company’s recent positive news has attracted the attention of analysts. Both Canaccord Genuity and ROTH MKM have issued "Buy" recommendations for the shares. The price targets for the NASDAQ-listed company are between USD 8.00 and USD 10.00. This means that the shares, which are currently trading at USD 1.87, still have substantial upside potential.

    Evotec - Takeover rumors and management change

    Evotec has undergone a significant change in management. Following Werner Lanthaler's resignation and Mario Polywka's retirement, Christian Wojczewski takes over the role of CEO. Wojczewski, a PhD chemist with extensive experience in the healthcare industry, brings with him valuable expertise gained at Linde Healthcare and Mediq. His primary task will be to regain investors' trust. The Company also appears to be exposed to potential takeover attempts, as the share price has fallen significantly since the beginning of the year.

    To guard against a possible hostile takeover, Wojczewski has commissioned Bank of America to develop a defence concept. Although no concrete offer has yet been made, private equity companies are said to have already shown interest. In addition to the challenges in the management environment, there are also positive developments at Evotec. The partnership with Bristol Myers Squibb in the field of neurology has reached an important milestone. A neurodegeneration program has entered advanced preclinical development, resulting in a research payment of USD 20 million. The partnership has been in place since 2016 and aims to develop disease-modifying treatments for neurodegenerative diseases.

    There were also positive signals from the Tubulis investment. Tubulis has received Fast Track approval from the FDA for the antibody-drug conjugate candidate TUB-040 in platinum-resistant ovarian cancer. The US Department of Defense selected the subsidiary Just-Evotec Biologics for the Manufacturing Optimization Program to optimise the development and manufacturing of mAb antibodies to improve responsiveness in crisis situations. Operationally, things are progressing, but whether this will be reflected in the numbers will be revealed to investors on August 14 when the second-quarter figures are presented. The share has recently moved significantly away from the lows of EUR 7.215 and is currently trading at EUR 9.75.


    In summary, exciting developments are currently taking place on the stock markets for Varta, Cardiol Therapeutics, and Evotec, which entail both opportunities and risks. Risks for small shareholders exist above all at Varta, even if the potential involvement of Porsche in the subsidiary V4Drive Battery GmbH could provide short-term relief. Cardiol Therapeutics has made remarkable progress in the development of innovative cardiac therapies with CardiolRx™, which shows promising results in the treatment of pericarditis and thus offers a significant opportunity for long-term growth. Evotec is facing important changes and possible takeover rumors while continuing to deliver operational success through strategic partnerships and new developmental milestones in neurology and oncology.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Fabian Lorenz on July 17th, 2024 | 07:30 CEST

    Siemens Energy share down 50%? Now time to buy Rheinmetall, Bayer, and Saturn Oil + Gas?

    • Mining
    • Oil
    • Defense
    • Pharma
    • renewableenergies

    Can the Siemens Energy share halve in value? At least, that is what the analysts at Bernstein think, who have set a price target of EUR 15. After a strong rally, the focus is now back on the Company's problem areas, such as India. Rheinmetall, on the other hand, is recommended as a "Buy". Can the armaments group thus end its sideways movement? In an initial study, analysts see around 50% upside potential for Saturn Oil & Gas. The oil company intends to significantly increase its free cash flow in the coming years but is considered undervalued compared to its peers. Some analysts see even more potential. Analysts are cautious about Bayer shares. In addition to the well-known legal disputes, operational issues are also a burden.

    Read

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.

    Read

    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.

    Read